KATHERINE STERLING: Open Payments
NPI 1255919817 · ZACHARY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 39 payments from 15 companies in 2025. Trend: 2023 $1,503 · 2024 $774 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 2 | $227 |
| Novo Nordisk Inc | 15 | $201 |
| Neurocrine BioSciences, Inc. | 1 | $122 |
| GlaxoSmithKline, LLC. | 4 | $73 |
| Dexcom, Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| GENZYME CORPORATION | 1 | $44 |
| Edwards Lifesciences Corporation | 1 | $27 |
| Abbott Laboratories | 1 | $21 |
Products named: Auvelity, INGREZZA, Ozempic, Rybelsus, Dexcom G6 Transmitter, TRELEGY ELLIPTA, VOQUEZNA, DUPIXENT.
Industry payments across LA — which companies pay providers there.
